Product Images Aripiprazole

This is a description for a medication called Aripiprazole 2mg. The medication comes in a container of 30 uncoated tablets that are green to light green in color with a mosaic appearance. Each tablet contains 2mg of aripiprazole. The tablets are modified rectangle shaped with debossing “AN896" and “2” on one side and plain on the other side. The medication guide needs to be dispensed separately. The lot number is 00000 and the expiration date is 00/00/00. The medication is manufactured by Amneal Pharmaceuticals in Ahmedabad, India, and is relabeled by Proficient Rx LP in Thousand Oaks, CA. The product ID is RA096530, and the NDC number is 63187-965-30. The medication should be stored at 20 to 25°C (68° to 77°F) and kept out of the reach of children.*

This text seems to show a table or a report regarding the effect of other drugs on Aripiprazole. It lists different drugs and their categories such as inhibitors, inducers, gastric acid blockers, and others. However, there is no additional detail regarding the actual effect of these drugs, except for a table that shows the fold change and 90% CI of Aripiprazole relative to a reference level without interacting drugs.*

This is a list of drugs that can potentially affect the pharmacokinetics of aripiprazole, including inhibitors and inducers of certain enzymes that metabolize aripiprazole, such as CYP enzymes, and other drugs. The chart shows the fold change in aripiprazole concentration in the presence of these interacting drugs, relative to the reference without any interacting drug.*

The text mentions the "Effect of Aripiprazole on Other Drugs" and lists various drugs and enzymes such as CYP2D6 and UGT1A4. The text also includes fold change data and a graph with percentages. Some of the listed drugs include dextromethorphan, warfarin, omeprazole, valproate, and lorazepam. However, the output contains some errors and non-readable characters, so it is difficult to determine the precise context and meaning of the text.*

The text describes different variables related to special populations, such as poor vs. extensive metabolizer, female vs. male gender, age groups (18-64 vs. 265 years old), different levels of hepatic impairment (mild, moderate, severe vs. normal), and severe renal impairment. The last part of the text seems to refer to PK (pharmacokinetics) and presents a graph that shows the Avipiprazole Fold Change and 90% CI in relation to a reference, with different values of relative change.*

The text represents data from a study comparing the relapse rates of aripiprazole versus placebo in a group of subjects over time. The graph shows the proportion of subjects experiencing relapse over a period of 364 days from randomization. The number of subjects at risk in each treatment group is also provided.*